Journal
ANNALS OF HEPATOLOGY
Volume 21, Issue -, Pages -Publisher
ELSEVIER ESPANA
DOI: 10.1016/j.aohep.2020.05.007
Keywords
Hepatitis C virus chronic infection; Hepatocellular carcinoma; Direct-acting antivirals; Chronic liver disease
Categories
Ask authors/readers for more resources
The development of DAAs has revolutionized chronic hepatitis C treatment, but controversy remains regarding its association with hepatocellular carcinoma incidence and recurrence.
The development of direct-acting antivirals (DAAs) has been a turning point in chronic hepatitis C treatment. With an efficacy rate on viral eradication close to 100% and an excellent safety profile, they have replaced interferon-based treatments as first-line therapy for hepatitis C virus (HCV). Following the encouraging results observed during the first years with these treatments, new publications suggested an unexpectedly high incidence of hepatocellular carcinoma (HCC) in patients previously treated with DAAs as well as a higher HCC recurrence rate in them. The possible interaction between DAAs and HCC and its impact on HCC incidence and recurrence still remains controversial. The aim of the present work is to review the current state of the matter by analyzing studies that evaluate the association between chronic hepatitis C treatment with DAAs and the development of HCC either de novo or as a recurrence. Following this, clinical practice recommendations are done. (C) 2020 Fundacion Clinica Medica Sur, A.C. Published by Elsevier Espana, S.L.U.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available